McN3716
CAS: 69207-52-9
Ref. 3D-UCA20752
1mg | Descontinuado | ||
5mg | Descontinuado | ||
10mg | Descontinuado | ||
25mg | Descontinuado | ||
50mg | Descontinuado |
Informação sobre produto
- (±)-2-Tetradecyl-2-oxiranecarboxylic Acid Methyl Ester
- 2-Oxiranecarboxylic Acid, 2-Tetradecyl-, Methyl Ester
- 69207-52-9
- McN 3716
- Methyl 2-tetradecylglycidate
- Methyl palmoxirate
- NSC 359682
- Oxiranecarboxylic acid, 2-tetradecyl-, methyl ester
McN3716 is a reversible inhibitor of the enzyme 3-phosphoinositide-dependent protein kinase 1 (PDK1) that blocks the phosphorylation of Akt on Ser473. McN3716 has been shown to inhibit the metabolic pathway in vitro in vivo models and to reduce hepatic steatosis, which is a result of its inhibition of PDK1. McN3716 also inhibits mitochondrial membrane potential, which leads to cell death. McN3716 has been shown to have an antidiabetic effect in humans and may be used as an anti-diabetic agent for type 2 diabetes mellitus.
McN3716 binds reversibly to PDK1 and this binding blocks the phosphorylation of Akt at Ser473, leading to reduced activity of enzymes such as glycogen synthase kinase-3β(GSK3β), which are important for glucose metabolism. This drug has been shown to increase insulin sensitivity and inhibit hepatic steatosis through